GlassScriptPhysician profile
Hayden Orgeron
NPI 1457960759
$11,423.68
in general payments reported to CMS, 2019-2025
30 companies · $3,511 in 2025
The $3,511 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $583 · 2022: $684 · 2023: $1,880 · 2024: $4,765 · 2025: $3,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,585 · Consulting Fee: $930 · Education: $633 · Travel and Lodging: $8.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,584.61 |
| Consulting Fee | $930.00 |
| Education | $632.89 |
| Travel and Lodging | $8.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $1,357.28 | 2023-2024 | Vtama |
| Abbvie INC. | $1,349.89 | 2021-2025 | |
| Janssen Biotech, INC. | $1,135.17 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $855.68 | 2022-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $828.35 | 2023-2025 | |
| Lilly USA, LLC | $760.15 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $753.80 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $731.34 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $506.12 | 2021-2025 | Dupixent |
| Amgen INC. | $349.03 | 2023-2025 | Otezla, Otezla |
| Journey Medical Corporation | $331.97 | 2022-2024 | |
| Pfizer INC. | $312.55 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $289.83 | 2022-2025 | Sotyktu |
| Vyne Pharmaceuticals INC. | $288.03 | 2021 | |
| Galderma Laboratories, L.P. | $259.91 | 2024-2025 | Nemluvio, Aklief |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $164.38 | 2025 | Vtama |
| Ucb, INC. | $160.94 | 2024-2025 | Bimzelx |
| Botanix Sb INC | $145.95 | 2025 | Sofdra |
| Gilead Sciences, INC. | $125.00 | 2024 | |
| Stemline Therapeutics INC. | $121.82 | 2022 | |
| Janssen Pharmaceuticals, INC | $120.14 | 2021 | |
| Edwards Lifesciences Corporation | $100.92 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $98.00 | 2023-2025 | Cabtreo, Jublia, Siliq |
| Scynexis, INC. | $87.24 | 2022 | |
| Leo Pharma INC. | $82.17 | 2023-2025 | Adbry |
| Kyowa Kirin, INC. | $30.48 | 2024 | Poteligeo |
| Boston Scientific Corporation | $25.82 | 2024 | Watchman Flx |
| Allergan, INC. | $23.49 | 2022 | |
| Verrica Pharmaceuticals INC. | $18.97 | 2025 | Ycanth |
| Mayne Pharma Commercial LLC | $9.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayden Orgeron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.